Cyclic AMP-Dependent Protein Kinase A Regulates the Alternative Splicing of CaMKIIδ by Gu, Qingqing et al.
Cyclic AMP-Dependent Protein Kinase A Regulates the







1Department of Cardiology, The Affiliated Hospital of Nantong University, Nantong, Jiangsu, People’s Republic of China, 2Jiangsu Key Laboratory of Neuroregeneration,
Nantong University, Nantong, Jiangsu, People’s Republic of China
Abstract
Ca
2+/calmodulin-dependent protein kinase (CaMK) IId is predominantly expressed in the heart. There are three isoforms of
CaMKIId resulting from the alternative splicing of exons 14, 15, and 16 of its pre-mRNA, which is regulated by the splicing
factor SF2/ASF. Inclusion of exons 15 and 16 or of exon 14 generates dAo rdB isoform. The exclusion of all three exons gives
rise to dC isoform, which is selectively increased in pressure-overload-induced hypertrophy. Overexpression of either dBo r
dC induces hypertrophy and heart failure, suggesting their specific role in the pathogenesis of hypertrophy and heart
failure. It is well known that the b-adrenergic-cyclic AMP-dependent protein kinase A (PKA) pathway is implicated in heart
failure. To determine the role of PKA in the alternative splicing of CaMKIId, we constructed mini-CaMKIId genes and used
these genes to investigate the regulation of the alternative splicing of CaMKIId by PKA in cultured cells. We found that PKA
promoted the exclusion of exons 14, 15, and 16 of CaMKIId, resulting in an increase in dC isoform. PKA interacted with and
phosphorylated SF2/ASF, and enhanced SF2/ASF’s activity to promote the exclusion of exons 14, 15, and 16 of CaMKIId,
leading to a further increase in the expression of dC isoform. These findings suggest that abnormality in b-adrenergic-PKA
signaling may contribute to cardiomyopathy and heart failure through dysregulation in the alternative splicing of CaMKIId
exons 14, 15, and 16 and up-regulation of CaMKIIdC.
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2+ handling plays an important role in
the pathogenesis of cardiac hypertrophy and heart failure. Ca
2+/
calmodulin–dependent kinase II (CaMKII) is a critical transducer
of Ca
2+ signaling in the heart. Cardiac-specific overexpression of
CaMKII induces a hypertrophic phenotype that rapidly transi-
tions to dilated cardiomyopathy with ventricular dysfunction, loss
of intracellular Ca
2+ homeostasis, and premature death [1,2,3,4].
Inhibition of CaMKII by either pharmacological or genetic
approaches reverses heart failure–associated changes (i.e., arrhyth-
mias, hypertrophy, and dysfunction) in animal models of structural
heart disease [5,6]. Upregulation of CaMKII expression and
activity have been reported to be a general feature of heart failure
in humans and in animal models [7,8,9,10,11].
CaMKII has four isoforms named a, b, c andd. CaMKIId is the
predominant isoform in the heart [12] and is required for
pathological cardiac hypertrophy and remodeling after pressure
overload. Cardiomyocyte expresses three splice variants, A, B and
C, of CaMKIId as a result of the alternative splicing of exons 14,
15 or 16 of its pre-mRNA. Inclusion of exon 15 and 16 or exon 14
generates CaMKIIdA or CaMKIIdB. CaMKIIdC is produced by
exclusion of all these exons (Fig. 1A,B). The dA isoform was
previously described as a neuronal CaMKIId isoform [13] and is
associated with the T-tubules. This isoform also is expressed in
neonatal heart and begins to switch off 30 days after birth [14].
The B isoform targets CaMKIId to nucleus due to exon 14, which
contains a nuclear localization signal, and plays a key role in
hypertrophic gene expression [15]. The dC isoform is the cytosolic
CaMKII and affects excitation-contraction (EC) coupling through
phosphorylation of Ca
2+-regulatory proteins [16]. Overexpression
CaMKIIdA in transgenic mice enhances EC coupling and induces
heart failure. Moreover, transgenic mice with overexpression of
either CaMKIIdB or CaMKIIdC also develop cardiac hypertro-
phy or heart failure [17]. Therefore, dysregulation in CaMKIId,
including its alternative splicing, may be involved in the
pathogenesis of cardiac hypertrophy and heart failure.
Splicing factor 2 or alternative splicing factor (SF2/ASF), also
termed serine/arginine-rich splicing factor 1 (SRSF1), regulates
both alternative splicing and constitutive splicing of many genes.
Cardiac-specific-knockout of SF2/ASF causes the retention of
CaMKIIdA in the adult mouse and suppression of dB and dC
isoforms, suggesting that it plays critical role in the alternative
splicing of CaMKIId [18]. SF2/ASF is a phosphoprotein. Its
function and localization is highly regulated by phosphorylation. It
is well known that many kinases phosphorylate SF2/ASF and
regulate its biological function. We recently found that PKA
phosphorylates SF2/ASF in vitro and in cultured cells and regulates
its function in tau exon 10 inclusion [19].
b-adrenergic receptor plays a central role in sympathetic
regulationof cardiac function.Catecholamines acts on b-adrenergic
receptor and activates adenylyl cyclase, which catalyzes cAMP
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e25745formation, via the stimulatory G protein (Gs). Subsequently, cAMP
binds onto the regulatory subunits of PKA (cyclic AMP-dependent
protein kinase), resulting in their dissociation from the catalytic
subunits and in activation of PKA [20]. Activated PKA phosphor-
ylates regulatory proteins involved in cardiac EC coupling and
energy metabolism. It is well known that abnormalities of b-
adrenergic-PKA pathway have been implicated as important
determinants of cardiac hypertrophy and heart failure. Chronic
heart failure is associated with an increase in circulating
catecholamines [21]. Overexpressionof b1-AR or Ga ´s in transgenic
mice develops cardiomyopathy and heart failure [22,23]. The
transgenic mice that express the catalytic subunit of PKA in the
heart develop dilated cardiomyopathy with reduced cardiac
contractility, arrhythmias, and susceptibility to sudden death. As
seen in human heart failure, these abnormalities correlate with
PKA-mediated hyperphosphorylation of the cardiac ryanodine
receptor/Ca
2+-release channel, which enhances Ca
2+ release from
the sarcoplasmic reticulum, and phospholamban, which regulates
the sarcoplasmic reticulum Ca
2+-ATPase [24]. Therefore, dysreg-
ulated PKA plays a specific role for in the pathogenesis of heart
failure.
However, the relationship between PKA signaling and CaM-
KIId alternative splicing, both of which are related with
hypertrophy and heart failure, is unclear. In the present study,
by using mini-CaMKIId-gene, consisting of exons 12, 13, 14, 15,
16, and 17 and introns 12, 13, 14, 15, 16 and 17, we determined
the role of PKA on the alternative splicing of CaMKIId. We found
that SF2/ASF promoted the exclusion of exons 14, 15 and 16 and
led to an increase of CaMKIIdC expression and a decrease of the
expression of CaMKIIdA and dB. Phosphorylation of SF2/ASF
by PKA further enhanced SF2/ASF function in the regulation of
the alternative splicing of CaMKIId.
Results
Alternative splicing of exons 14, 15 and 16 generates
three splicing variants of the mini-CaMKIId genes
In order to investigate the regulation of the alternative splicing
of CaMKIId in cultured cells, we first constructed a mouse mini-
CaMKIId-gene, pCI/CaMKIIdE12–E17, consisting of exons
12,13,14,15,16 and 17, and introns 12, 13, 14, 15, and 16
(Fig. 1A), and then transfected the mini-gene into HEK-293FT
cells. After 48 hr transfection, RNA was extracted and subjected to
RT-PCR for measurement of the alternative splicing of exons 14,
15 and 16 of CaMKIId. We observed three alternative splicing
products (Fig. 1C). The size of the upper band matched the
product of exon 14 exclusion. The middle band was the product of
exclusion of exons 15 and 16, and the lower band was the PCR
product of exclusion of exons 14, 15 and 16. To confirm these
three bands to be the splicing products of the mini-gene of
CaMKIId, we sequenced the PCR products. The data showed
that these three RT-PCR products were lack of exon 14, of exons
15 and 16 and of exons 14, 15, and 16, respectively (Fig. 1C).
These results suggest that the mini-gene of CamKIId, pCI/
CaMKIIdE12–E17, is able to generate three alternative splicing
products of CaMKIId exon 14, 15 and 16, which represent
CaMKIIdA, B, and C, respectively.
To test whether exon 12 and intron 12 affects the alternative
splicing, we also constructed pCI/CaMKIIdE13–E17 mini-CaM-
KIIa ¨-gene, consisting of exons 13,14,15,16 and 17, and introns 13,
14, 15, and 16 (Fig. 1C), and transfected it into COS7 cells. After
48 hr transfection, we measured its splicing products with RT-
PCR. We found that, similar to pCI/CaMKIIdE12–E17, pCI/
CaMKIIdE13–E17 also generated three splicing products, which
represented CaMKIIdA, B, and C, respectively (Fig. 1D). Thus,
Figure1.Alternativesplicing ofCaMKIId exons14,15,and16 generates threesplicing variants, correspondingtoCaMKIId isoformsA,
B,andC,respectively. A and B, Schematic diagram of the alternative splicing of exons 14, 15, and 16 of mini -CaMKIId-genes, pCI/CaMKIIdE12–E17 (A)
and pCI/CaMKIIdE13–E17 (B). C and D, Three splicing variants was generated from mini-CaMKIId gene, pCI/CaMKIIdE12–E17 (C) or pCI/CaMKIIdE13–E17 (D),
after transfection into HEK-293T or COS7 cells, respectively, for 48 hrs. The total RNA was used for measurement of the splicing products with RT-PCR.
doi:10.1371/journal.pone.0025745.g001
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CaMKIIdE12–E17 and pCI/CaMKIIdE13–E17, were alternatively
spliced and these two mini-genes can be used for the study of the
alternative splicing of CaMKIId.
PKA regulates the alternative splicing of CaMKIId
To investigate whether PKA regulates the alternative splicing of
CaMKIId, we transfected the HEK293T cells with pCI/
CaMKIIdE13–E17 for 40 hr, and treated the cells with various
concentration of forskolin to activate PKA for 8 hr. Forskolin
treatment increased PKA activity presented by increased phos-
phorylation of CREB at Ser133 (Fig. 2A). We measured the
alternative splicing products of CaMKIId exons 14, 15, and 16
with RT-PCR. We found that forskolin treatment promoted the
exclusion of exons 14, 15, and 16, and suppressed the inclusion of
exon 14 and of exons 15 and 16, resulting in an increase in
CaMKIIdC and a decrease in CaMKIId A and B expression dose-
dependently (Fig. 2B). These results suggest that PKA may
regulate the alternative splicing of CaMKIId.
To confirm the regulation of forskolin on CaMKIId splicing via
activation of PKA, we co-expressed PKA catalytic a subunit
(PKA-Ca), a dominant isoform in heart [25], with the pCI/
CaMKIIdE13–E17, and then measured the splicing products of
exons 14, 15, and 16 of CaMKIId. Consistent with forskolin
treatment, overexpression of PKA-Ca increased PKA activity to
phosphorylate CREB (Fig. 2C) and promoted the exclusion of
exons 14, 15, and 16, resulting in an increase in the expression of
CaMKIIdC, and a decrease in the expressions of CaMKIIdA and
CaMKIIdB significantly (Fig. 2D).
Figure 2. PKA promotes exclusion of exons 14, 15, and 16 of CaMKIId. A, Forskolin treatment activated PKA. HEK-293T cells were transfected
with pCI/CaMKIIdE13–E17 for 40 hrs and then treated with 10 mM forskolin for 8 hrs. The cells were subjected to Western blots for detection of PKA
activity with anti-phosphorylated CREB at Ser133 and anti-CREB. B, Forskolin treatment promoted the exclusion of exons 14, 15, and 16, resulting in
an increase in CaMKIIdC expression. HEK-293T cells were transfected with pCI/CaMKIIdE13–E17 for 40 hrs and then treated with 10 mM forskolin for
8 hrs. The splicing products were measured with RT-PCR. Each splicing product was quantitated by densitometry, and the percentage of each
splicing form was calculated. C, Overexpression of PKA-Ca increased PKA activity. HEK-293T cells were co-transfected with pCI/CaMKIIdE12–E17 and
pCI/PKA-Ca for 48 hrs. The PKA activity in the cells was measured by phosphorylation of CREB at Ser133 with Western blots. D, Overexpression of
PKA-Ca promoted the exclusion of exons 14, 15, and 16 of CaMKII
TM. HEK-293T cells were cotransfected with pCI/CaMKIIdE13–E17 and pCI/PKA-Ca for
48 hrs. The splicing products were measured with RT-PCR. Each splicing product was quantitated by densitometry, and the percentage of each
splicing form was calculated. The Data are presented as mean 6 S.D. *p,0.05 versus control treatment.
doi:10.1371/journal.pone.0025745.g002
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of CaMKIId
Previous studies have identified that knockout of SF2/ASF
caused deregulation of the alternative splicing of CaMKIId [18].
To determine the regulation of SF2/ASF on the alternative
splicing of exons 14, 15, and 16 of the CaMKIId mini-gene, we co-
transfected pCEP4/SF2/ASF with pCI/CaMKIIdE12–E17 into
COS7 cells, and then measured the products of its alternative
splicing. We found that overexpression SF2/ASF significantly
promoted the exclusion of exons 14, 15 and 16, resulting in an
increase of CaMKIIdC and a decrease of CaMKIIdA and B
(Fig. 3A, B). Similarly, overexpression of SF2/ASF also promotes
CaMKIIdC expression in pCI/CaMKIIdE13–E17 transfected
HEK293T cells (Fig. 3B, C). These results further confirmed that
SF2/ASF could regulate the alternative splicing of exons 14, 15,
and 16 and ASF promotes the exclusion of exons 14, 15, and 16 of
CaMKIId.
PKA phosphorylates and interacts with SF2/ASF
To elucidate whether PKA regulates SF2/ASF’s activity to
promote the exclusion of CaMKIId exons 14, 15, and 16, we first
determined whether PKA phosphorylates SF2/ASF in vitro. We
incubated GST-SF2/ASF or GST with PKA catalytic subunit and
[c-
32P]-ATP in reaction buffer for 30 min at 30uC, and then the
reaction products were subjected to SDS-PAGE and autoradio-
graph for detection of
32P incorporation. We observed that GST-
SF2/ASF, but not GST, had
32P incorporation, suggesting that
SF2/ASF is phosphorylated by PKA (Fig. 4A).
To investigate the interaction between PKA and SF2/ASF, we
performed GST pull-down assay and co-immunoprecipitation (co-
IP). For GST pull down assay, we incubated GST-SF2/ASF or
GST alone with rat brain extract. After extensively washing, the
proteins pulled down by GST-SF2/ASF or GST were subjected to
Western blots with anti-PKA-Ca. We found that PKA-Ca was
pulled-down from rat brain extracts by GST-SF2/ASF, but not by
GST (Fig. 4B), suggesting that SF2/ASF may interact with PKA-
Ca.
Similar results were obtained from co-IP studies. We overex-
pressed HA tagged SF2/ASF (SF2/ASF-HA) in HEK-293FT cells
and immunoprecipitated SF2/ASF with anti-HA. The immuno
complex using anti-HA was subjected to Western blot analysis. We
found that anti-HA immunoprecipitated SF2/ASF-HA, and that
PKA-Ca subunit was co-immunoprecipitated by anti-HA. These
Figure 3. SF2/ASF promotes the exclusion of exons 14, 15, and 16 of CaMKIId. A and B, Overexpression of SF2/ASF promoted the exclusion
of exons 14, 15, and 16 of pCI/CaMKIIdE12–E17 in COS7 cells. PCI/CAMKIIdE12–E17 was co-transfected with pCEP4/SF2/ASF into COS7 cells for 48 hr. The
splicing products were measured with RT-PCR (A). Each splicing product was quantitated by densitometry and the percentage of each splicing form
was calculated (B). C and D, Overexpression of SF2/ASF promoted the exclusion of exons 14, 15, and 16 of pCI/CaMKIIdE13–E17 in HEK-239T. PCI/
CAMKIIdE12–E17 was co-transfected with pCEP4/SF2/ASF into HEK-293T cells for 48 hr. The splicing products were measured with RT-PCR (C). The each
splicing product was quantitated by densitometry and the percentage of each splicing form was calculated (D). The Data are presented as mean 6
S.D. *p,0.05 versus control treatment.
doi:10.1371/journal.pone.0025745.g003
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(Fig. 4C).
To elucidate the interaction of SF2/ASF with PKA in intact
cells, we transfected pCEP4/SF2/ASF into HeLa cells, and then
treated the cells with 10 mM Forskolin. Their subcellular locali-
zation was determined by confocal microscopy. We observed that,
without forskolin treatment, PKA-Ca was mainly located in the
cytoplasm and that SF2/ASF was localized extensively in the
nucleus (Data not shown). Forskolin treatment appeared to
promote PKA catalytic subunit translocation into the nucleus to
co-localize with SF2/ASF (Fig. 4D).
PKA enhances SF2/ASF role in the regulation of CaMKIId
splicing
To investigated whether PKA affects SF2/ASF-mediated
alternative splicing of CaMKIId exons 14, 15, and 16, we co-
transfected pCEP4/SF2/ASF with pCI/CaMKIIdE13–E17 into
HEK293T cells. After 40 hrs transfection, we treated the cells with
10 mM forskolin or 20 mM isoproterenol for 8 hr for activating
PKA and then measured the splicing products of CaMKIId exons
14, 15, and 16. We found that both forskolin and isoproterenol
treatments enhanced the role of SF2/ASF to promote the
exclusion of CaMKIId exons 14, 15, and 16, resulting in a further
increase in CaMKIIdC expression (Fig. 5).
Discussion
The alternative splicing of exons 14, 15, and 16 of CaMKIId
pre-mRNA generates three different splice variants, A, B and C.
SF2/ASF plays an important role in the alternative splicing of
CaMKIId [18]. In the present study, we constructed, for first time,
two mini-genes of CaMKIId, in which exons 14, 15, and 16 were
able to be alternatively spliced to generate the spliced variants
Figure 4. PKA phosphorylates and interacts with SF2/ASF. A, Recombinant GST-SF2/ASF or GST was incubated with PKA in the presence of
[c-
32P]ATP at 30uC for 10 min, and the reaction mixture was then separated by SDS-PAGE and visualized with Coommassie blue staining (lower panel)
or autoradiograph (upper panel). B, PKA-Ca was pull-down by SF2/ASF. GST-SF2/ASF or GST coupled onto glutathione-Sepharose or glutathione-
Sepharose (GSH-beads) was incubated with rat brain extract. After extensively washing, the bound proteins were analyzed by Western blots
developed with anti-GST or anti-PKA-Ca. C, PKA-Ca was co-immunoprecipitated by anti-HA. SF2/ASF tagged with HA were expressed in HEK-293FT
cells for 48 h. The cell extracts were immunoprecipitated with anti-HA, and the immunoprecipitates were subjected to Western blots developed with
anti-HA and anti-PKA-Ca. D, HeLa cells were transfected with pCEP4/SF2/ASF and treated without (Con) or with forskolin (Fors) for 30 min, followed
by triple immunofluorescence staining.
doi:10.1371/journal.pone.0025745.g004
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these mini-genes, we confirmed the role of SF2/ASF in the
promotion of exclusion of exons 14, 15, and 16 of CaMKIId. PKA
interacted with and phosphorylated SF2/ASF and further
enhanced the SF2/ASF function in promotion of exclusion of
CaMKIId exons 14, 15, and 16. Therefore, abnormalities of b-
adrenergic-PKA pathway during pathogenesis of hypertrophy and
heart failure may course the dysregulation of the alternative
splicing of CaMKIId exons 14, 15, and 16, resulting in an
imbalance in the generation of CaMKIIdA, B and C isoforms,
which may contribute to the hypertrophy and heart failure.
The expression of CaMKIId isoforms is developmentally
regulated in the heart. CaMKIIdB and C are presented in the
adult mammalian myocardium, but CaMKIIdA is expressed in
neonatal heart and begins to switch off 30 days after birth [18].
These three isoforms of CaMKIId have different subcellular
localization, which determines their specific roles in regulating
cardiac function. The dA isoform was previously described as a
neuronal CaMKIId isoform [13] and associates with the T-tubules
where key Ca
2+ channels and activated CaMKIId are concen-
trated [14]. As a nucleus CaMKIId, the B isoform plays a key role
in hypertrophic gene expression [15], whiles the cytoplasmic dC
isoform affects EC coupling through phosphorylation of Ca
2+
regulatory proteins [16]. Overexpression of the dB isoform in the
nucleus or the dC isoform in the cytoplasm in transgenic mice both
give rise to marked decrease in diastolic Ca
2+, transient amplitude,
and caffeine-releasable Ca
2+ content in the sarcoplasmic reticu-
lum, all of which seem to reflect a general heart failure phenotype
[4,17].
SF2/ASF plays a crucial role in the alternative splicing of
CaMKIId exons 14, 15, and 16. Knockout of SF2/ASF in the
mouse heart promotes the inclusion of exons 15 and 16 and
suppresses exclusion of exons 15 and 16 or exclusions of all exons,
resulting in an increase in the expression of CaMKIIdA and a
decrease in the expression of CaMKIIdB and CaMKIIdC [18].
The dysregulation of CaMKIId isoforms in the SF2/ASF deficient
mice appears to enhance EC coupling and hypercontraction in
isolated cardiomyocytes, the phenotype resulting from the
targeting of the kinase to the T-tubules where several key Ca
2+
handling proteins are located. In this study, we observed that
overexpression of SF2/ASF promoted exclusion of exons 14, 15,
and 16, leading to increased expression of CaMKIIdC, which is
consistent with above in vivo study.
The function and distribution of SF2/ASF is highly regulated
by phosphorylation. Site/regional phosphorylation impacts SF2/
ASF function and subcellular localization differentially. Phosphor-
ylation of SF2/ASF by Clk and SRSK enhances its function in the
regulation of alternative splicing [26]. Phosphorylation of SF2/
ASF at Ser227, Ser234 and Ser238 by Dyrk1A suppresses its
function on the alternative splicing of tau exon 10 [27]. PKA
phosphorylates SF2/ASF and promotes its function in the
alternative splicing of CaMKIId. PKA is a Ser/Thr kinase and
is activated by the binding of cAMP onto its regulatory subunits.
We recently have demonstrated that PKA effectively phosphor-
ylates SF2/ASF and enhances its function in promotion of tau
exon 10 inclusion [19]. Here, we found that up-regulation of PKA
enhances SF2/ASF-promoted exclusion of CaMKIId exons 14,
15, and 16, resulting in further decrease in dA and dB and increase
in dC isoform of CaMKII.
Cytosolic CaMKIIdC regulates cardiac excitation-contraction
coupling and maladaptive cardiac remodeling, while the nucleus
form ofCaMKIId,dB,is involved in the regulation of gene expression.
Figure 5. PKA activation enhances SF2/ASF-promoted exclusion of exons 14, 15, and 16 of CaMKIId. A, HEK-293FT cells were transfected
with pCI/CaMKIIdE13–E17 for 40 hrs and then treated with 10 mM forskolin or 20 mM isoproterenol for 8 hrs. The splicing products were measured with
RT-PCR. Each splicing product was quantitated by densitometry and the percentage of each splicing form was calculated. The Data are presented as
mean 6 S.D. *p,0.05 versus control treatment. B, Proposed mechanism by which abnormalities of b-adrenergic-PKA-pathway dysregulates the
alternative splicing of exons 14, 15, and 16 of CaMKIId via SF2/ASF.
doi:10.1371/journal.pone.0025745.g005
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regulated in response to oxidative stress and ischemia/reperfusion
injury [28]. Overexpression of CaMKII-a ¨C promotes apoptosis,
whereas overexpression of CaMKIIdB protects cardiomyocytes
against oxidative stress-, hypoxia-, and angiotensin II -induced
apoptosis [28]. Overexpression of dC in the transgenic mice develops
a dilated cardiomyopathy. Isolated myocytes from the mice are
enlarged and exhibit reduced contractility and altered Ca
2+ handing
[4]. The expression of dC isoform of CaMKII is selectively increased
and its phosphorylation elevated as early as 2 days and continuously
for up to 7 days afterpressure overload [4], suggesting the involvement
of CaMKIIdC activation in the pathogenesis of dilated cardiomyop-
athy and heart failure. Down-regulation of CaMKIIdC expression
may prevent hypertrophy and heart failure caused by dysregulated
b-adrenergic-PKA pathway. Therefore, the roles of PKA in the
regulation of alternative splicing of CamKIId and in the pathoge-
nesis of cardiomyopathy and heart failure in vivo remain to be
elucidated.
Materials and Methods
Plasmids, antibodies, and other reagents
CaMKIId minigene pCI/CaMKIIdE12–E17 or pCI/CaM-
KIIdE13–E17, comprising CaMKIId exons 12, 13, 14, 15, 16 and
17 and introns 12, 13, 14, 15, 16, was generated by PCR from
mouse genomic DNA as described below. The expression
constructs for human PKA-Ca was generated by reverse-
transcription PCR from RNA isolated from normal human
neuronal progenitor cells (Lonza, Walkersville, MD, USA) and
confirmed by DNA sequence analysis. PKA-Ca tagged with HA
was cloned into pCI vector via Sal I and Not I sites. pCEP4/SF2/
ASF-HA was a gift from Dr. Tarn of the Institute of Biomedical
Sciences, Academia Sinica, Taiwan. pGEX-2T/SF2/ASF was
constructed by PCR amplification from pCEP4-SF2/ASF-HA
and sub-cloning into pGEX-2T to express GST-fusion proteins of
SF2/ASF. The catalytic subunit of PKA and the monoclonal anti-
HA were bought from Sigma (St. Louis, MO, USA). Polyclonal
Anti-PKA-Ca was from Abcam (Cambridge, UK) and polyclonal
anti-PKA-Cb was from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Peroxidase-conjugated anti-mouse and anti-rabbit IgG
were obtained from Jackson ImmunoResearch Laboratories (West
Grove, PA, USA); Alexa 488-conjugated goat anti-mouse IgG,
Alexa 555-conjugated goat anti-rabbit IgG and TO-PRO-3 iodide
(642/661) were from Invitrogen (Invitrogen, Carlsbad, CA, USA).
ECL Kit was from Amersham Pharmacia (Amersham Bioscience,
Piscataway, NJ, USA), and [c-32P]ATP and [
32P]-orthophosphate
were from MP Biomedicals (Irvine, CA, USA).
Construction of mini-CaMKIId-genes, pCI/CaMKIIdE12–E17
and pCI/CaMKIIdE13–E17
C57BL6 mouse was from the laboratory animal center of
Nantong University. The protocol was approved according to the
Animal Care and Use Committee of Nantong University and the
Jiangsu Province Animal Care Ethics Committee (Approval ID:
SYXK(SU)2007-0021). Mouse genomic DNA was extracted from
C57BL6 mouse tail with Dneasy Blood and Tissue kit (Qiagen,
Germany) and used as a template to amplify genomic DNA of
CaMKIId from exon 12 to exon 17 including introns (E12–E17,
12,475 bp) with two pairs of primers (Fig. 1a). Set 1 of primers
(forward, 59cgACGCGTatttctttgatagggcgccatcttgacaac39; reverse,
59acgcGTCGACaaagagccttcttctgtgg39) was used to generate
6825 bp fragment. Set 2 of primers (forward, 59acgcGTCGACa-
catgggagcttggaatg39; reverse, 59ataagaatGCGGCCGCgcctcaagcc-
tacctttcacgtcttcatcc39). The PCR products were digested by Mlu I
and Sal I, and Sal I and Not I respectively, and inserted into pCI/
neo vector by restriction sites of Mlu I and Not I, which named
pCI/CaMKIIdE12–E17. The sequences of the mini-gene was
confirmed by sequencing analysis.
By using pCI/CaMKIIdE12–E17 as the template, we ampli-
fied the genomic DNA of CaMKIId from exon 13 to exon 17
with primers (forward, 59cgACGCGTtcattttgca gcagccaagagtttatt-
gaag39; reverse, 59ataagaatGCGGCCGCgcctcaagcctacctttcacgtc
ttcatcc39) to amplify the genomic DNA of CaMKIId from exon 13
to exon 17 and inserted into pCI/neo by Mlu I and Not I, which
was named pCI/CaMKIIdE13–E17.
Cell culture and transfection
COS-7, HeLa, and HEK-293FT cells (ATCC, Manassa, VA,
USA) were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (Invitrogen)
at 37uC. All transfections were performed in triplicate with
FuGENE 6 (Roche Diagnotics, Indianapolis, IN, USA) in 12-well
plate or 4 well-chamber. The cells were transfected with FuGENE
6 for 48 h according to the manufacturer’s instructions.
In vitro phosphorylation of SF2/ASF by PKA
GST and GST-SF2/ASF (0.2 mg/ml) was incubated with PKA
catalytic subunit in a reaction buffer consisting of 50 mM 40 mM
HEPES (pH 6.8), 10 mM b-mercaptoethanol, 10 mM MgCl2,
1.0 mM EGTA and 0.2 mM [c-
32P]ATP (500 cpm/pmol). After
incubation at 30uC for 30 min, the reaction was stopped by boiling
with an equal volume of 26Laemmli sample buffer. The reaction
products were separated by SDS-PAGE. Incorporation of
32P was
detected by exposure of the dried gel to phosphor-image system.
GST pull-down of PKA by SF2/ASF
GST and GST-SF2/ASF were purified by affinity purification
with glutathione-Sepharose, but without elution from the beads.
Thesebeads coupledwith GST and GST-SF2/ASF wereincubated
with crude extract from rat brain homogenate in buffer (50 mM
Tris-HCl, pH 7.4, 8.5% sucrose, 50 mM NaF, 1 mM Na3VO4,
0.1% Triton X-100, 2 mM EDTA, 1 mM PMSF, 10 mg/ml
aprotinin, 10 mg/ml leupeptin and 10 mg/ml pepstatin). After 4 h
incubation at 4uC, the beads were washed with washing buffer
(50 mM Tris-HCl, pH7.4, 150 mM NaCl and 1 mM DTT) six
times, the bound proteins were eluted by boiling in Laemmli sample
buffer and the samples were subjected to Western blot analysis.
Co-immunoprecipitation of PKA by SF2/ASF
HEK-293FT cells were transfected with pCEP4-SF2/ASF-HA for
40 h as described above and treated with 10 uM forskolin for 8 h, and
then the cells were washed twice with PBS, and lysed by sonication in
lysate buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 50 mM NaF,
1m MN a 3VO4, 2 mM EDTA, 1 mM PMSF, 2 mg/ml aprotinin,
2 mg/ml leupeptin and 2 mg/ml pepstatin). The cell lysate was
centrifuged at 16,0006g for 10 min and incubated with anti-HA
overnight at 4uC, and then protein G beads were added. After 4 h
incubation at 4uC, the beads were washed with lysate buffer twice and
with TBS twice, and bound proteins were eluted by boiling in Laemmli
sample buffer. The samples were subjected to Western blot analysis
with the indicated primary antibodies.
Co-localization of PKA with SF2/ASF
HeLa cells were plated in 24-well plates onto coverslips one day
prior to transfection at 50–60% confluence. The cells were then
transfected with pCEP4/SF2/ASF-HA as described above. After
40 h transfection, the cells were treated with 10 mM forskolin for
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and fixed with 4% paraformaldehyde in PBS for 30 min at room
temperature. After washing with PBS, the cells were blocked with
10% goat serum in 0.2% Triton X-100-PBS for 2 h at 37uC, and
incubated with rabbit anti-HA antibody (1:200) and mouse anti-
PKACa (1:50) overnight at 4uC. The cells were then washed and
incubated for 1 h with secondary antibodies (Alexa 488-conjugated
goat anti-mouse IgG and Alexa 555-conjugated goat anti-rabbit IgG,
1:1000) plus TO-PRO-3 iodide at room temperature. The cells were
washed with PBS, mounted with Fluoromount-G and observed with
a Nikon TCS-SP2 laser-scanning confocal microscope.
Quantitation of splicing products of CaMKIId exons 14,
15, and 16 by reverse transcription-PCR (RT-PCR)
Total cellular RNA was isolated from cultured cells by using the
RNeasy Mini Kit (Qiagen, GmbH, Germany). One microgram of
total RNA was used for first-strand cDNA synthesis with Oligo-
(dT)15–18 by using the Omniscript Reverse Transcription Kit
(Qiagen). PCR was performed by using PrimeSTAR
TM HS DNA
Polymerase (Takara Bio Inc., Otsu, Shiga, Japan) with primers
(forward, 59 GGTGTCCACTCCCAGTTCAA 39; reverse, 59
GTCTTCATCCTCAATGGTGG TG 39) to measure alternative
splicing of CaMKIId exons 14, 15, and 16. The PCR conditions
were: 98uC for 3 min, 98uC for 10 sec and 68uC for 40 sec for 25–
30 cycles and then 68uC 10 min for extension. The PCR products
were resolved on 1.5% agarose gels. Each splicing product was
quantitated by densitometry using the Molecular Imager system
(Bio-Rad, Hercules, CA, USA), and the percentage of each
splicing form was calculated.
Statistical analysis
All data are expressed as the means6SD. Data points were
compared by unpaired two-tailed Student’s t test. A value of
p,0.05 was considered statistically significant.
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